In a long-awaited decision, the U.S. Supreme Court has just ruled that companies may not patent naturally occurring segments of human DNA.
However, patents are allowed if a company cre…ates synthetic composite DNA, also known as cDNA, handing a legal victory to the Salt Lake City-based Myriad Genetics, which was sued by the Association for Molecular Pathology and other groups.
The second ruling is no favor to women who are genetically susceptible to breast and ovarian cancers. Myriad Genetics has developed an expensive test to isolate the BRCA1 and BRCA2 DNA strands.
Read the full article in ModernHealthcare.com